吳斌主管藥師
上海交通大學醫學院附屬仁濟醫院藥劑科
擅長領域:?
執業經歷: 職 稱:副研究員 職 務:藥學部主任助理 院 區:東院 科 室:藥劑科 醫療專長:自獲得第一個上海市教委優秀青年教師科學基金開始(2009年),將研究集中具有用藥復雜、社會負擔重的疾病為研究對象,以運籌統計和臨床決策為研究手段,以評價和比較不同治療藥物的成本及效果效用為目標開展工作。 教育經歷 2013/09 – 2014/09,多倫多大學Leslie Dan藥學院與多倫多大學附屬總醫院(學習) 2005/09 – 2008/06,上海交通大學,博士 2002/09 – 2005/06,中國科學院上海藥物研究所,碩士, 1997/09 – 2002/06,南京醫科大學 本科 論文著作 1.期刊論文(SCI收錄第一作者/通訊作者): [1]. Wu B, Dong B, Xu Y, Zhang Q, Shen J, Chen H, Xue W: Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PLoS One 2012, 7(3):e32530. (IF = 3.73) [2]. Wu B, Chen H, Shen J, Ye M: Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China. Clin Ther 2011, 33(10):1446-1455. (IF = 2.23) [3]. Wu B, Ye M, Chen H, Shen JF: Costs of Trastuzumab in Combination With Chemotherapy for HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: An Economic Evaluation in the Chinese Context. Clin Ther 2012, 34(2):468-479. (IF = 2.23) [4]. Wu B, Miao Y, Bai Y, Ye M, Xu Y, Chen H, Shen J, Qiu Y: Subgroup economic analysis for glioblastoma in a health resource-limited setting. PLoS One 2012, 7(4):e34588. (IF = 3.73) [5]. Wu B, Li T, Chen H, Shen J: Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis. Value in Health 2010, 13(5):592-600. (IF = 2.191) [6]. Wu B, Wilson A, Wang F-F, Wang S-L, Wallace DJ, Weisman MH, et al. Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china. PLoS One. 2012; 7(10): e47373. (IF = 3.73) [7]. Y. Bai, M. Ye, H. Cao, X. Ma, Y. Xu and Wu B *. Economic evaluation of radiotherapy for early breast cancer after breast-conserving surgery in a health resource-limited setting, Breast cancer research and treatment 136 (2012), pp. 547-557. (Corresponding author) (IF = 4.469) [8]. Wu B, J. Shen and H. Cheng, Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China, BMC Health Serv Res 12 (2012), p. 385. (IF = 1.773) [9]. J. Zhu, T. Li, X. Wang, M. Ye, J. Cai, Y. Xu and Wu B *. Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis. BMC Cancer 2013, 13:39. (Corresponding author) (IF = 3.333) [10]. Ben-Juan Wei, Yi-Jun Chen, Li Yu , Wu B. Periodontal Disease and Risk of Preeclampsia: A Meta-Analysis of Observational Studies. PLoS One. 2013. Doi:10.1371/journal.pone.0070901. (IF = 3.73) [11]. Wu B, Kun L, Liu X, He B: Cost-Effectiveness of Different Strategies for Stroke Prevention in Patients with Atrial Fibrillation in a Health Resource-Limited Setting. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2013. 2013 Sep 19. [Epub ahead of print]. PMID: 24048510 (IF = 2.673) 獲得榮譽 ?、?吳斌,林厚文, Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B, 中國藥學會,優秀論文二等獎,2013.11 ?、?吳斌,葉明, Initial Chemotherapy with or without Maintenance Therapy in Patients with Advanced Non-Small-Cell Lung Cancer: An Economic Decision Analysis, 中國藥學會,優秀論文二等獎,2012.11 ?、?吳斌,呂良敬, Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china, 中華醫學會,風濕病2012年會優秀論文三等獎, 2012.5 ?、?吳斌, 類風濕關節炎患者使用生物制劑治療的經濟學研究, 上海市藥學會,醫院藥學2012年會優秀論文三等獎, 2012.5 ?、?吳斌, Subgroup economic analysis for glioblastoma in a health resource-limited setting, 上海市藥學會,醫院藥學2010年會優秀論文一等獎,2010.11 ?、?吳斌, 中國乙肝患者使用口服核苷類似物治療的藥物經濟學研究, 上海交通大學醫學院,醫院藥學2010年會優秀論文一等獎, 2010.12 ?、?吳斌,邱永明, 腦膠質瘤治療的藥物經濟學決策路徑研究, 中華醫學會,國際神經外科2010年會優秀論文三等獎, 2010.9 ?、?吳斌,沈金芳, Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis, 中國藥學會,優秀論文三等獎,2012.11 詳細介紹
*以下號源由妙手醫生專業認證,僅展示近4周號源